[organization name]	
Summary of Safety and Clinical Performance for [medical device]	_

Commented [AES1]: Include the name of the medical device or medical device group for which this summary is prepared.

- 10		10000					12:12	1	•	233
	JO	cu	me	nt	ali	ПC	rm	at	ю	n
-										-

Version:
Created by:
Approved by:
Date of version:

Commented [AES2]: This is a mandatory section and cannot be deleted, each change in the summary, person who prepared and approved the summary, date and version must be recorded.

Change history

Date Version Created by Description of change

Commented [AES3]: This is a mandatory section and cannot be deleted, each change in the summary must be recorded.

Table of contents

1.	IDEN	ITIFICATION OF THE DEVICE	3
	1.1.	IDENTIFICATION OF DEVICE OR DEVICE FAMILY	. :
	1.2.	IDENTIFICATION OF THE MANUFACTURER	. :
	1.3.	DEVICE DESCRIPTION	. :
	1.4.	INTENDED PURPOSE	. :
2.	LIST	OF APPLICABLE STANDARDS	4
3.	SUM	IMARY OF RESIDUAL RISKS.	4
4.	CLIN	ICAL EVALUATION	4
_			
5.	POST	T-MARKET CUNICAL FOLLOW-UP	

[organization name]	
1. Identification of the device	
1.1. Identification of device or device family	Commented [AES4]: Include information that will identify you
Name of medical device or a family of medical devices	
Dimension, sizes	
Sufficient services	
No consultation	
Confusion according to from the of the CHAPITE and Product Bencharase.	Commented [AESS]: Write in the classification of the medical
1.2. Identification of the manufacturer	
Manufacturer	
	Commented [AES6]: Include concise physical and chemical descriptions, including materials; whether the device incorporated
1.3. Device description	Commented [AES7]: Make a list of all versions, dimensions,
Description of device	Commented [AES8]: List:
	An overview of the previous generation or generations of the device produced by the manufacturer, where such devices exist;
List of all versions and dimensions	
Bellevine to province and confine generalizes of the Bernel	Commented [AES9]: Accessories means any other devices and
Control of the Contro	7/
Storryton of ess accessorie of spatroline).	Commented [AES10]: If there is no any alternative use, you
THE COLUMN TWO COLUMN	Commented [AES11]: Provide the exact description of the intended purpose as described in the device's IFU.
	In exceptional cases where an instruction for use is not required, describe the generally recognized modalities of use, including:
	*name of disease or condition, clinical form, stage, severity *symptoms or aspects to be treated/managed/ diagnosed
1.4. Intended purpose	
Intended use/purpose in alignment with Instructions for use (IFU)	
Summary of Safety and Clinical ver. [version] from [date] Page Performance	⊋3 of 5
©2023 This template may be used by clients of Advisera Expert Solutions Ltd. www.advisera.com in accordance with the Licen Agreement.	se

[organization name]		
Target population		Commented [AES12]: Include information about all
Indications		Commented [AES13]: Include information about all warr
Core andrones		Commented [AES14]: Include information about all
Marriage		Commented [AES15]: Include information about the use the medical device that will need training.
Property		
Suggested users and training needed for medical	device usage	Commented [AES16]: If you are using the ISO 13485 & N Integrated Toolkit, you can delete a table and write: "The list:
Suggested users	Specificating	
		Commented [AES17]: List all standards used in the
2. List of applicable standards		Commented [AES18]: List whether the standards is harmonized or not.
Name of the standard	a word later	If non-harmonized standards are used in areas where there at harmonized standards, verify the justification that the standard adequately document compliance for the requirements.
		Commented [AES19]: Include justification for why you h.
3. Summary of residual risks		Commented [AES20]: Include brief description of the
Summary of residual risks		Commented [AES21]: Include the Clinical Evaluation Plan Clinical Evaluation Report, Literature Research and Review Pro
4. Clinical evaluation		Commented [AES22]: Describe briefly the conclusions for the Clinical Evaluation Report.
Summary of clinical evaluation report		
Summary of Safety and Clinical ver. [version	n] from [date]	Page 4 of 5

Agreement.

[organization name]			
·			
5. Post-market clinical fol	low-up		
Summary of post-market clinical	follow-up		Commented [AES23]: Include here a short description of t
		*	The control of the co
Summary of Safety and Clinical	ver. [version] from [date]	Page 5 of 5	

Performance

 $@2023 \ This \ template \ may \ be \ used \ by \ clients \ of \ Advisera \ Expert \ Solutions \ Ltd. \ www.advisera.com \ in \ accordance \ with \ the \ License$